The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Laetitia MarziLudmila SzabovaMelanie GordonZoe Weaver OhlerShyam K SharanMichael L BeshiriMoudjib EtemadiJunko MuraiKathleen KellyYves Pommier

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Our results provide a rationale for molecularly designed clinical trials with the indenoisoquinolines as single agents and in combination with PARP inhibitors in HRD cancers expressing SLFN11.

Keyphrases

dna repair
dna damage
clinical trial
oxidative stress
phase ii
randomized controlled trial
open label
young adults
wild type
phase iii